[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598722":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":139,"collaborators":19,"id":141,"slug":19,"hasResults":142,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":142,"sex":148,"minAge":149,"maxAge":19,"enrollmentInfo":150,"targetDuration":19,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":172,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"Kelonia Therapeutics, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"KLN-1010","EXPERIMENTAL","Drug: KLN-1010 specified dose given once",[13],"Drug: KLN-1010",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Given at specified dose one time",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"SVP Clinical Development","CONTACT","617-223-7349","clinicaltrials@keloniatx.com",[27,47,63,80,97,113,128],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":35,"coordinates":36},"Point",[37,38],-117.97729,34.13945,{"lat":38,"lon":37},[41,45],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":44},"Scott Goldsmith, MD","626-218-2405","sgoldsmith@coh.org",{"name":42,"role":46,"phone":19,"phoneExt":19,"email":19},"PRINCIPAL_INVESTIGATOR",{"facility":48,"status":29,"city":49,"state":31,"zip":50,"country":33,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Stanford University","Palo Alto","94304",{"type":35,"coordinates":52},[53,54],-122.14302,37.44188,{"lat":54,"lon":53},[57,61],{"name":58,"role":23,"phone":59,"phoneExt":19,"email":60},"Sharan Claire","650-721-4091","sharanclaire@stanford.edu",{"name":62,"role":46,"phone":19,"phoneExt":19,"email":19},"Surbhi Sidana, MD",{"facility":64,"status":29,"city":65,"state":66,"zip":67,"country":33,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Emory University Hospital","Atlanta","Georgia","30322",{"type":35,"coordinates":69},[70,71],-84.38798,33.749,{"lat":71,"lon":70},[74,78],{"name":75,"role":23,"phone":76,"phoneExt":19,"email":77},"Bryan Burton","404-778-1780","Bryan.james.burton@emory.edu",{"name":79,"role":46,"phone":19,"phoneExt":19,"email":19},"Nisha Joseph, MD",{"facility":81,"status":29,"city":82,"state":83,"zip":84,"country":33,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Providence Portland Medical Center","Portland","Oregon","97213",{"type":35,"coordinates":86},[87,88],-122.67621,45.52345,{"lat":88,"lon":87},[91,95],{"name":92,"role":23,"phone":93,"phoneExt":19,"email":94},"Laurel Brookhyser","503-215-1979","canrsrchstudies@providence.org",{"name":96,"role":46,"phone":19,"phoneExt":19,"email":19},"Stacey Lewis, MD",{"facility":98,"status":29,"city":99,"state":100,"zip":101,"country":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"The Royal Prince Alfred","Camperdown","New South Wales","2050","Australia",{"type":35,"coordinates":104},[105,106],151.17642,-33.88965,{"lat":106,"lon":105},[109],{"name":110,"role":23,"phone":111,"phoneExt":19,"email":112},"Dr. Jose Valencia-Klug","+61 2 9515 5721","jose.valencia-klug@health.nsw.gov.au",{"facility":114,"status":29,"city":115,"state":116,"zip":117,"country":102,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"Peter MacCallum Cancer Centre","Melbourne","Victoria","3000",{"type":35,"coordinates":119},[120,121],144.96332,-37.814,{"lat":121,"lon":120},[124],{"name":125,"role":23,"phone":126,"phoneExt":19,"email":127},"Hannah Pahl","+61 3 8559 7851","PCCTU.HaemC@petermac.org",{"facility":129,"status":29,"city":115,"state":116,"zip":130,"country":102,"cosmosGeoPoint":131,"geoPoint":133,"contacts":134},"The Alfred Paula Fox Melanoma and Cancer Centre","3004",{"type":35,"coordinates":132},[120,121],{"lat":121,"lon":120},[135],{"name":136,"role":23,"phone":137,"phoneExt":19,"email":138},"Prof. Andrew Spencer","+61 3 9076 2000","andrew.spencer@monash.edu",{"type":140,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100598722",false,"NCT07075185","A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","inMMyCAR","Inclusion Criteria:\n\n* Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease\n* Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody\n* Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1\n* Participants must have acceptable laboratory values as defined by the protocol\n\nExclusion Criteria:\n\n* Participants must not have known central nervous system (CNS) involvement with myeloma\n* Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis\n* Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy\n* Participants cannot require systemic steroids for any condition","ALL","18 Years",{"count":151,"type":152},70,"ESTIMATED","INTERVENTIONAL",[155],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.",[158,159,160,161,162,163,164,165,166,167,168,169,170,171],"Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy",[173,174,175,176],"in vivo CAR-T","multiple myeloma","gene therapy","BMCA","2026-04-22",{"date":179,"type":180},"2026-04-24","ACTUAL",{"date":182,"type":180},"2025-07-16",{"date":184,"type":152},"2042-05",{"name":5,"class":6},7]